Physician profile
Steven D Brown
NPI 1811998008
$19,372.80
in general payments reported to CMS, 2019-2025
57 companies · $2,064 in 2025
The $2,064 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,783 · 2020: $1,891 · 2021: $3,444 · 2022: $3,554 · 2023: $3,597 · 2024: $2,040 · 2025: $2,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,700.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,837.84 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Glaxosmithkline, LLC. | $2,040.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,944.59 | 2019-2025 | |
| Novo Nordisk INC | $1,897.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,751.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,160.44 | 2019-2025 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,048.88 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $710.04 | 2019-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $589.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $538.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $443.21 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Allergan, INC. | $428.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $420.44 | 2019-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $400.46 | 2020-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $305.41 | 2019-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.